Primmune’s Melanoma Clinical Study Advisory Board is comprised of key opinion leaders in oncology that have contributed to pivotal Phase III trials which have defined the standard of care for melanoma and head and neck cancers. In particular, the advisory board includes many co-authors of the Phase III NADINA study which established neo-adjuvant combinatorial immune therapy as a standard of care for melanoma:
  • Miles Andrews, BSc(Hons), BMBS(Hons), FRACP, PhD, Medical Oncologist and Senior Research Fellow at the Alfred Hospital, at Monash University, Melbourne, Australia. NADINA co-author.
  • Victoria Atkinson, MBBS, FRACP, Senior Medical Oncologist, Principle Investigator, and Professor at University of Queensland Clinical School of Medicine, Brisbane, Australia. NADINA co-author.
  • Ezra Cohen, MD, Chief Medical Officer Oncology, Tempus Labs, Inc., Chicago IL, USA
  • Adnan Khatak, MBBS, FRACP, PhD, Professor and Consultant Medical Oncologist, Hollywood Private Hospital and Fiona Stanley Hosptial Perth, Australia. NADINA co-author.